Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.

This study found that a topical solution of caffeine and minoxidil 2.5% was more effective in treating androgenetic alopecia than minoxidil 2.5% alone.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This study used computational methods to identify six molecules, with jamogenin being particularly promising, that effectively bind to and inhibit the enzyme linked to male pattern hair loss, suggesting these compounds could be explored further for hair growth potential.

This study reported that peanut callus extract, rich in resveratrol, significantly stimulated hair growth and reduced hair loss in an in vitro model and a clinical trial, showing promise as a cosmetic bioactive ingredient.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

Isolation stress in rats reduces brain enzyme levels, affecting dopamine function.

This study found that Eclipta alba extracts exhibit 5α-reductase inhibitory activity, with the methanolic extract showing a higher concentration of β-sitosterol compared to petroleum ether extract, indicating potential for treating androgenic conditions like male pattern baldness.

This study found that Lepidium sativum seed extract showed potential in treating alopecia in rats by reducing 5(alpha)-dihydrotestosterone levels and improving hair length compared to minoxidil.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.

This article describes the growth and characteristics of saw palmetto and its fruit but reports no new research results.

This abstract reports funding sources for ongoing research and does not present any study results.

This study found that methylation of the 5-AR 2 promoter region may lead to low or absent 5-AR 2 protein expression in some human adult prostate tissues.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This article discusses the familiarity of identifying male androgenetic alopecia but presents no new research findings.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

This study observed that using only a 5 alpha-reductase inhibitor was ineffective for treating androgen-dependent hair loss in women, possibly due to differing copper levels influencing enzyme activity.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This in vitro study found sex chromosome differences affect steroidogenic enzyme activity and androgen receptor expression in human skeletal muscle cells, showing varied responses to testosterone exposure between 46XY and 46XX cells.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This study suggests that a mixture of Chrysanthemum zawadskii, peppermint, and Glycyrrhiza glabra promotes hair growth and reduces hair loss markers in testosterone-treated cells and mice.

This study found that coffee berry extract demonstrated anti-aging properties in skin and hair cells, showing significant anti-collagenase activity and stimulating hair-related gene expression, suggesting its potential for use in cosmeceuticals.

Androgenetic alopecia may be irreversible due to the detachment of a muscle from hair follicles.

In this study, topical minoxidil 7% with dutasteride 0.5 mg showed higher efficacy but more adverse effects compared to minoxidil 7% with finasteride 1 mg for treating androgenetic alopecia.

This study reports that the compound CS-891 can inhibit 5alpha-reductase activity in the dermal papillae of human hair follicles, suggesting potential for treating androgenetic alopecia.

This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.

This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.